PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Protalix BioTherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.56−0.06 (-2.29%)
Close on Oct 19, 2026
- Market cap
- $211.35M
- P/E (TTM)
- 11.1
- Dividend yield
- –
Share price
+$0.70 (+37.63%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Protalix BioTherapeutics, Inc. grew revenue 30.1% to $80.62M over the twelve months to Jun 30, 2026. Operating income rose 183.1% to $23.29M, moving the operating margin from 13.3% to 28.9%. Free cash flow was $7.67M.
Revenue
$80.62M
+30.1% vs. a year earlier
Operating income
$23.29M
+183.1% vs. a year earlier
Free cash flow
$7.67M
TTM Q2 2026
EPS, diluted
$0.23
+475.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $211.35M
- P/E ratio
- 11.1
- Price to sales
- 2.62
- Price to book
- 2.96
- Dividend yield
- –
- Free cash flow yield
- 3.63%
Fundamentals
- Revenue
- $80.62M
- Net income
- $18.95M
- EPS, diluted
- $0.23
- Free cash flow
- $7.67M
- Book value per share
- $0.86
- Diluted shares
- 83M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$80.62M+30.1% YoY
Gross profit
$55.79M+56.5% YoY
Operating income
$23.29M+183.1% YoY
Net income
$18.95M+201.9% YoY
EPS, diluted
$0.23+475.0% YoY
Free cash flow
$7.67M
Reported periodTrailing twelve months